Iijima Masami 4

What Happened

• Masami Iijima, a director of Takeda Pharmaceutical Co. (TAK), disposed of 2,152 shares (reported as a derivative disposition) on July 10, 2026 for a weighted-average price of ¥4,931.20, totaling ¥10,611,942.
• On July 1, 2026 Iijima was granted two awards: 1,800 RSUs and 1,937 Tax Obligation Awards (total 3,737 units). The RSUs vest on June 1, 2029. The Tax Obligation Awards are the economic equivalent of shares that were converted/settled to cover tax obligations; any remaining proceeds from associated share dispositions were delivered to the reporting person on July 10.

Key Details

• Transaction dates: Grants on 2026-07-01; disposition on 2026-07-10.
• Sale price: weighted average ¥4,931.20; sale prices ranged from ¥4,883 to ¥5,045 (filing offers to provide exact breakdown on request).
• Reported amounts: 1,800 RSUs (award), 1,937 Tax Obligation Awards (award), 2,152 shares disposed (derivative sale).
• Consideration: RSU grants reported at $0.00 (typical for awards); disposition reported as derivative (D).
• Shares owned after the transactions: not specified in the provided filing data.
• Filing timeliness: not indicated in the provided information.

Context

• The July 10 sale appears tied to tax-settlement mechanics for Tax Obligation Awards (i.e., awards converted/settled to cover tax liabilities rather than an open-market investment sale).
• RSU awards vest in 2029, so those are long-dated and not immediately tradable.
• This activity mixes routine award grants and a cash/derivative disposition for tax purposes; it should not be read alone as a bullish or bearish signal.